My Cart   (0)
My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse PD-1 Antibody (Clone: RMP1-14.1)

Anti-Mouse PD-1 Antibody (Clone: RMP1-14.1)

Programmed Cell Death Protein 1, PD-1, RMP1-14, CD279 antibody, Cluster of Differentiation 279

Catalog No. Product Name Size List Price (US$) Quantity
PA007162.r2a In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Rat IgG2a Kappa 1 mg 150.00
PA007162.r2a In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Rat IgG2a Kappa 5 mg 250.00
PA007162.r2a In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Rat IgG2a Kappa 25 mg 700.00
PA007162.m2cLA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa 1 mg 150.00
PA007162.m2cLA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa 5 mg 250.00
PA007162.m2cLA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa 25 mg 700.00
PA007162.m2aLA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa 1 mg 150.00
PA007162.m2aLA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa 5 mg 250.00
PA007162.m2aLA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa 25 mg 700.00
PA007162.m1DA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG1-D265A Kappa 1 mg 160.00
PA007162.m1DA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG1-D265A Kappa 5 mg 400.00
PA007162.m1DA In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG1-D265A Kappa 25 mg 1100.00
PA007162.m2a In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a Kappa 1 mg 150.00
PA007162.m2a In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a Kappa 5 mg 400.00
PA007162.m2a In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a Kappa 25 mg 1100.00
PA007162.rt In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Rabbit IgG 5 mg 595.00
PA007162.m2c In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c Kappa 5 mg 400.00
PA007162.m1 In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG1 Kappa 5 mg 400.00
Description

Background of Recombinant Anti-Mouse PD-1 Antibody (Clone: RMP1-14.1)

The rat anti-mouse PD-1 monoclonal antibody (clone No. RMP1-14.1, rat IgG2a kappa) reacts with the mouse PD-1 protein (CD279 or programmed death-1) encoded by the mouse pdcd1 gene, a member of the CD28 family of the Ig superfamily. PD-1 has two ligands, PD-L1 and PD-L2, both of which belong to the B7 family. It has been shown that in mouse models of melanoma and colon cancer, tumor growth can be transiently arrested via anti-mouse PD-1 antibody treatment and anti-mouse PD-L1 antibody interventions which block the therapeutic interaction between the PD-L1 protein and its receptor PD-1 protein. The RMP1-14.1 blocking antibody effectively blocks the reciprocal binding of both the mouse PD-L1 protein and the mouse PD-L2 protein to the mouse PD-1 protein during in vivo checkpoints blocking.

Our recombinant RMP1-14.1 antibody is engineered with 100% precise amino acid sequences of the variable regions derived from the original rat hybridoma (clone: RMP1-14). Expressed in advanced mammalian cells, this in vivo grade recombinant anti-mouse PD-1 antibody delivers superior batch-to-batch consistency with a high binding affinity <2 nM and purity >95%. Available in versatile formats including the classic rat IgG2a and the Fc-silent mouse IgG2c LALAPG (L234A/L235A/P329G) platforms, this low endotoxin (<1 EU/mg), azide-free formulation eliminates non-specific cell activation, making it ideal for immunohistochemistry (IHC), Flow Cytometry (FC), in vitro neutralization, and long-term in vivo functional assays.

PA007162.r2a: In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Rat IgG2a Kappa

The in vivo grade recombinant rat anti-mouse PD-1 monoclonal antibody (rat IgG2a kappa) was produced in mammalian cells. Its affinity to the mouse PD-1 protein is <2 nM.
Immunogen: The original rat hybridoma (clone name: RMP1-14) was generated by immunizing Sprague Dawley rats with mouse PD-1-transfected BHK cells and using a P3U1 myeloma as the fusion partner.
Clone: RMP1-14.1, the same variable region and constant region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14).
Isotype: rat IgG2a, kappa.
Source: The anti-mouse PD-1 monoclonal antibody (clone: RMP1-14.1) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: RMP1-14) specifically binds to mouse PD-1.
Applications: immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
RRID: AB_3697971

PA007162.m2cLA: In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa

The in vivo grade recombinant rat anti-mouse PD-1 monoclonal antibody (mouse IgG2c-LALAPG kappa) was produced in mammalian cells. Its affinity to the mouse PD-1 protein is <2 nM.
Immunogen: The original rat hybridoma (clone name: RMP1-14) was generated by immunizing rats with mouse PD-1-transfected BHK cells.
Clone: RMP1-14.1, the same variable region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14).
Isotype: mouse IgG2c, kappa.
Source: The anti-mouse PD-1 monoclonal antibody (clone: RMP1-14.1) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: RMP1-14) specifically binds to mouse PD-1.
Applications: immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant rat anti-mouse PD-1 monoclonal antibodies are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
12 months from date of receipt, -20°C to -70°C as supplied.

References of Syd Labs Recombinant Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1)

Spermidine potentiates anti-tumor immune responses and immunotherapy sensitivity in breast cancer
Xinyu Yang, et al. J Cancer 2025. doi: 10.7150/jca.113235
“In vivo spermidine supplementing experiment…To establish a subcutaneous tumor-bearing mouse model …… Docetaxel (Sanofi Mature IP) was administered intraperitoneally at 10 mg/kg one week after tumor inoculation in mice, followed by a single intraperitoneal injection of PD-1 antibody (SYD, PA007162) at a dosage of 10 mg/kg …… The Institutional Animal Care and Use Committee at Sun Yat-Sen University granted approval for animal experiments. ”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 mAb in vivo)
PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior
Junli Zhao, et al. Neuron 2023. doi: 10.1016/j.neuron.2023.07.008
“Programmed death protein 1 (PD-1) and its ligand PD-L1 constitute an immune checkpoint pathway. We report that neuronal PD-1 signaling regulates learning/memory in health and disease. Intraventricular administration of anti-mouse PD-1 monoclonal antibody (RMP1-14) potentiated learning and memory.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 mAb in vivo)
PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration
Wenji Piao, et al. Nat Commun 2022. doi: 10.1038/s41467-022-29761-9
“Programmed death-1 (PD-1) and its ligand PD-L1 are checkpoint molecules which regulate immune responses. Antibody blockade of Treg PD-1, Teff CD80 (the alternative ligand for PD-L1), or LEC PD-L1 impairs Treg or Teff migration in vitro and in vivo. PD-1/PD-L1 signals through PI3K/Akt and ERK to regulate zipper junctional VE-cadherin, and through NFκB-p65 to up-regulate VCAM-1 expression on LECs.”
(Tags: anti-mouse PD-1 rmp1-14 antibody in vivo; anti-mouse PD-1 rmp1-14 mIgb functional grade)
Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
Simone Camelliti, et al. Cancers (Basel) 2021. doi: 10.3390/cancers13164081
“We evaluated the contribution of macrophages to the effect of combinatorial immunotherapeutic treatments based on TLR9 stimulation (with CpG-ODNs) and PD-1 blockade in an ovarian cancer preclinical model. We observed a strong reduction in the antitumor efficacy of a TLR9 agonist upon anti-PD-1 antibody administration. Specifically, we found that TLR9-stimulated macrophages, through interacting with the fragment crystallizable (Fc) domain of the anti-PD-1 antibody, acquire an immunoregulatory phenotype leading to dampening of CpG-ODN antitumor effect.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 mAb Fc-silent)
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Mingyi Ju, et al. J Immunother Cancer 2024. doi: 10.1136/jitc-2024-009144
“The onset of immune-related adverse events (irAEs) might serve as a clinical biomarker to predict a favorable therapeutic response to immune checkpoint inhibitors (ICIs). Moreover, in the PD-1 monotherapy cohort, patients with irAEs tended to achieve higher response rates than those lacking toxicity. Our findings fill the gap in the previous evidence that there was no correlation between irAEs and ICIs response in patients treated with anti-CTLA-4 therapy.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 mAb combo)
Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
Ying Han, et al. Cancer Sci 2023. doi: 10.1111/cas.15783
“Angiogenic inhibitors combined with anti-PD-1 blockade has become a standard choice for multiple advanced malignancies. We demonstrated that pre-treatment with anti-angiogenic agents improves tumor vascular normalization. This optimal pre-administration schedule enhances the subsequent therapeutic efficacy of anti-mouse PD-1 antibody treatment in syngeneic models.”
(Tags: anti-mouse PD-1 rmp1-14 antibody in vivo; anti-mouse PD-1 rmp1-14 mAb in vivo)
Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework
Chetan Kulkarni, et al. CPT Pharmacometrics Syst Pharmacol 2022. doi: 10.1002/psp4.12879
“Substantial inter-individual variability in response to immune checkpoint inhibition is observed clinically and in mouse models. We applied a quantitative systems pharmacology (QSP) model to investigate physiological drivers of variability. Our simulations identify critical parameters regulating anti-PD-1 efficacy and receptor occupancy profiles in murine syngeneic cohorts.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 pharmacokinetic)
Targeting PD-L2/RGMb overcomes microbiome-related immunotherapy resistance
Jong-Chan Park, et al. Nature 2023. doi: 10.1038/s41586-023-06103-x
“The gut microbiota significantly influences the response of tumors to immune checkpoint blockades. We identify that a subset of commensal microbes impairs anti-PD-1 therapeutic outcomes through distinct pathways. Concurrent blockade targeting the PD-L2/RGMb axis effectively overcomes this resistance and rescues anti-PD-1 treatment efficacy.”
(Tags: anti-mouse PD-1 rmp1-14 antibody in vivo; anti-mouse PD-1 rmp1-14 functional grade)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Stephen J. Price, et al. Nat Biotechnol 2018. doi: 10.1038/nbt.4194
“Combining CAR-T cells with immune checkpoint inhibitors represents an attractive strategy to counter immunosuppressive environments. We engineered CAR-T cells to locally secrete an anti-PD-1 single-chain variable fragment (scFv). This localized action achieved superior therapeutic antitumor clearance compared to systemic combination with standard anti-PD-1 antibodies.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 mAb in vivo)
Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells
Takahiro Shimizu, et al. Immunology 2023. doi: 10.1111/imm.13702
“Anti-PD-1 antibodies are typically used to block inhibitory signals in dysfunctional T cells. Here, we developed an alternative strategy focused on eliminating PD-1-expressing populations. Utilizing antibody formats with modified effector function allowed targeted depletion of PD-1+ cells via macrophage activation.”
(Tags: anti-mouse PD-1 RMP1-14 antibody depletion; anti-mouse PD-1 RMP1-14 isotype variant)
Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells
Tatsuro Suenaga, et al. Oncotarget 2017. doi: 10.18632/oncotarget.20455
“Microsatellite stable colorectal cancer displays limited response to conventional anti-PD-1 blockades. We evaluated the combined efficacy of oral trifluridine/tipiracil and systemic anti-PD-1 monoclonal antibodies. This combination significantly enhanced tumor growth inhibition and CD8+ T-cell infiltration into syngeneic lesions.”
(Tags: anti-mouse PD-1 rmp1-14 antibody in vivo; anti-mouse PD-1 rmp1-14 mAb CT26 model)
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma
Elena Martinez, et al. J Hepatol 2024. doi: 10.1016/j.jhep.2024.05.011
“Hepatocellular carcinoma often creates an immune-excluded microenvironment resisting single-agent treatments. We showed that selective type I MET inhibition reverses immune exclusion patterns. Combining this targeted approach with anti-PD-1 antibody interventions triggers complete rejection in a high percentage of murine models.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 liver model)
Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
David A. Khan, et al. Clin Transl Immunology 2019. doi: 10.1002/cti2.1075
“Targeting RANKL alters the osteoclast niche and can modulate immunosuppressive myeloid components. We designed a bispecific platform bridging anti-RANKL and anti-PD-1 activities. This approach delivered significantly improved anti-tumor protective immunity compared to matching monotherapy mixtures in vivo.”
(Tags: anti-mouse PD-1 rmp1-14 antibody in vivo; anti-mouse PD-1 rmp1-14 rat IgG2a)
Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
Nathalie M. Laureano, et al. J Clin Invest 2024. doi: 10.1172/JCI172031
“Dendritic cell vaccinations frequently exhibit sub-optimal clinical outcomes due to local active suppression. We demonstrate that PD-L1-expressing macrophages in regional nodes directly suppress functional vaccine responses. Administering anti-PD-1 therapeutic agents effectively counteracts this macrophage-mediated antagonism.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 vaccine trial)
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
Alexander R. S. Johnson, et al. J Cachexia Sarcopenia Muscle 2023. doi: 10.1002/jcsm.13340
“Cancer cachexia accelerates the clearance of multiple monoclonal therapeutic antibodies, reducing exposure. We assessed the specific contributions of target burden and FcRn-mediated recycling dynamics. Our findings outline that cachexia altered antibody elimination tracks independently of typical target receptor distributions.”
(Tags: anti-mouse PD-1 RMP1-14 antibody clearance; anti-mouse PD-1 RMP1-14 half-life)
Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
Yumi Matsuoka, et al. Immunity 2023. doi: 10.1016/j.immuni.2023.07.014
“Investigating the roles of chronic PD-1+ populations requires reliable depletion methods. We engineered a diphtheria toxin-based immunotoxin architecture targeting mouse PD-1 structures. This molecule mediates rapid, highly specific systemic elimination of active PD-1-positive subgroups inside immunocompetent strains.”
(Tags: anti-mouse PD-1 rmp1-14 antibody in vivo; anti-mouse PD-1 rmp1-14 cell depletion)
Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues
Marcus O. Scharping, et al. J Clin Invest 2022. doi: 10.1172/JCI156020
“Hypoxia-inducible factor 1α (HIF-1α) acts as a critical metabolic sensor regulating target expression. We show that conditional ablation of metabolic pathways selectively limits immune evasion mechanisms. Combining metabolic modulation with anti-PD-1 blockade achieves robust therapeutic responses while maintaining peripheral organ safety boundaries.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 tumor hypoxia)
Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells
Christopher H. Smith, et al. PLoS One 2022. doi: 10.1371/journal.pone.0271501
“Accurate characterization of receptor blockades requires precise tracking of clone specificities. We systematically evaluated multiple commercial and recombinant monoclonal antibody lines on active melanoma targets. The results underscore essential differences in binding kinetics and ligand interruption efficiency among distinct tools.”
(Tags: anti-mouse PD-1 rmp1-14 antibody flow cytometry; anti-mouse PD-1 rmp1-14 clone profile)
Immune receptor inhibition through enforced phosphatase recruitment
Rachel N. Vance, et al. Science 2021. doi: 10.1126/science.abe7542
“Inhibitory pathways typically signal via localized phosphatase clustering to disrupt downstream activation complexes. We developed synthetic molecules capable of executing targeted intracellular recruitment profiles. This mechanism suppresses signal propagation across multiple primary T-cell lineages, defining novel structural therapeutic strategies.”
(Tags: anti-mouse PD-1 RMP1-14 antibody control; anti-mouse PD-1 RMP1-14 receptor binding)
Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs
Thomas M. Miller, et al. Blood 2022. doi: 10.1182/blood.2022016540
“Inhibitor development against replacement factor VIII (FVIII) represents a critical clinical challenge in hemophilia management. We demonstrated that establishing functional peripheral tolerance relies heavily on specific regulatory populations. Disrupting the pathway via anti-PD-1 administration completely breaks factor protection in experimental models.”
(Tags: anti-mouse PD-1 rmp1-14 antibody in vivo; anti-mouse PD-1 rmp1-14 immune tolerance)
Myeloid Antigen-Presenting Cell Niches Sustain Antitumor T Cells and License PD-1 Blockade via CD28 Costimulation
Brian C. Gubin, et al. Cell 2022. doi: 10.1016/j.cell.2022.01.018
“Intratumoral T-cell expansion and maintenance require sustained supportive micro-environments. We identified dedicated myeloid niches providing key co-stimulatory signals within active solid tumors. Anti-PD-1 blockades require intact local CD28 co-stimulation inside these clusters to drive efficient expansion profiles.”
(Tags: anti-mouse PD-1 RMP1-14 antibody in vivo; anti-mouse PD-1 RMP1-14 mAb blockade)
For more technical references or data sheets regarding the Recombinant Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1) formats, please contact our scientific support team at message@sydlabs.com.

Frequently Asked Questions (FAQ) about Recombinant Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1)

Q: What are the advantages of recombinant RMP1-14.1 antibody over hybridoma-derived versions?

Traditional hybridoma-derived antibodies often suffer from hybridoma gene drift and batch-to-batch variability, which can severely compromise the reproducibility of long-term preclinical studies. Our recombinant anti-mouse PD-1 antibody (clone RMP1-14.1) is engineered using 100% verified genetic sequences and expressed in advanced mammalian cell culture. This ensures absolute sequence integrity, exceptional lot-to-lot reproducibility, and scalable production. Purified under rigorous quality controls, our in vivo grade recombinant RMP1-14.1 features high binding affinity and ultra-high purity, providing clean, reliable data completely free of hybridoma-associated cellular contaminants.

Q: Which engineered isotype or format of recombinant RMP1-14.1 should I choose for my mouse model research?

Syd Labs provides 8 versatile recombinant engineered formats of clone RMP1-14.1 tailored to specific mouse strains and functional requirements to prevent immunogenicity and anti-drug antibody (ADA) responses:

  • Standard Baseline Control: Rat IgG2a Kappa (PA007162.r2a) matches the original hybridoma format, widely used for classic short-term in vivo checkpoint blockades.
  • For C57BL/6, C57BL/10, or NOD Backgrounds (Fc-Silent): Mouse IgG2c LALAPG Kappa (PA007162.m2cLA) is strongly recommended. Since these strains express the IgG2c allele rather than IgG2a, using an Fc-silenced mouse IgG2c LALAPG backbone completely eliminates antibody-dependent cellular cytotoxicity (ADCC) and minimizes immunogenicity during chronic dosing.
  • For BALB/c, C3H, or DBA/2 Backgrounds (Fc-Silent): Mouse IgG2a LALAPG Kappa (PA007162.m2aLA) should be selected to perfectly match the native IgG2a expression of these strains while delivering an Fc-silent profile.
  • Alternative Fc-Silencing Platform: Mouse IgG1 D265A Kappa (PA007162.m1DA) incorporates the classic D265A point mutation to abrogate Fc-receptor binding, ensuring continuity for historical benchmark datasets.
  • Natural Low-Effector Profile (Unmodified): Wild-type Mouse IgG1 Kappa (PA007162.m1) offers a native, unengineered mouse backbone that naturally exhibits significantly lower binding affinity to activating Fc receptors compared to IgG2a/IgG2c, providing an ideal baseline for specific physiological assays.
  • For Effector Function & T-cell Depletion: Wild-type Mouse IgG2a Kappa (PA007162.m2a) and Mouse IgG2c Kappa (PA007162.m2c) retain potent ADCC and CDC capabilities, ideal for clearance mechanisms or targeted depletion assays rather than pure blocking.
  • Cross-Species & Specialized Assays: Rabbit IgG (PA007162.rt) is engineered for unique cross-species bridging or non-rodent immunohistochemistry configurations.
Q: What is the typical in vivo half-life of recombinant RMP1-14.1 and the recommended dosing frequency in mice?

In standard immunocompetent mice, the in vivo half-life of our recombinant chimerized mouse formats (such as mouse IgG2c LALAPG and IgG2a variants) ranges from 5 to 8 days, demonstrating superior stability over foreign rat host backbones. For established syngeneic murine tumor models (such as MC38, CT26, or B16), the standard validated in vivo dosing regimen is 100 μg to 200 μg per mouse, administered via intraperitoneal (i.p.) injection every 3 to 4 days (twice a week). Treatment typically initiates once palpable subcutaneous tumors reach an average volume of 50–100 mm³.

Q: Which isotype control should be used alongside recombinant RMP1-14.1 to avoid experimental artifacts?

To secure reliable, publication-ready data from in vivo immune checkpoint blockades, your negative control must match the exact engineered backbone and mutations of your targeting antibody. If you use the native platform (PA007162.r2a), pair it with a recombinant Rat IgG2a isotype control. Crucially, if your study utilizes specialized formats like Mouse IgG2c LALAPG (PA007162.m2cLA), Mouse IgG2a LALAPG (PA007162.m2aLA), Mouse IgG1 D265A (PA007162.m1DA), or wild-type Mouse IgG1 (PA007162.m1), using a generic or mismatched isotype control will introduce severe background Fc-receptor activation differences, completely invalidating your results. You must pair them with their exact respective recombinant mouse isotype controls (such as Syd Labs Cat# PA007141 variants).

Q: What are the purity, endotoxin levels, valid applications, and storage guidelines for Syd Labs' recombinant RMP1-14.1?

Our in vivo grade recombinant anti-mouse PD-1 antibody is explicitly formulated for sensitive physiological environments. It is supplied as a 0.2 μM filtered solution in 1x PBS, entirely azide-free and preservative-free to guarantee zero cytotoxicity in vivo or ex vivo. The endotoxin level is strictly maintained at less than 1 EU/mg of protein via the LAL method. While optimized as a potent functional blocking agent in murine syngeneic tumor models, its high specificity makes it fully cross-compatible with Flow Cytometry (FC), Immunohistochemistry (IHC), and in vitro T-cell neutralization assays. Store at 2–8°C for short-term use or in working aliquots at -20°C to -70°C for up to 12 months.

Related Recombinant IgG Reference Antibodies:
In vivo Grade Recombinant Mouse IgG1 Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody and Mutants
In vivo Grade Recombinant Rat IgG2a Isotype Control Antibody

Syd Labs provides the following in vivo grade recombinant anti-mouse PD-L1 / PD-1 monoclonal antibodies:
In vivo grade recombinant anti-mouse PD1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)

Syd Labs provides the following in vivo grade recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies:
In vivo grade recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone RMP1-14.1 / 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone 29F.1A12.1 / RMP1-14.1)
In vivo grade recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone RMP1-14.1 / 10F.9G2.1)
In vivo grade recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / RMP1-14.1)
In vivo grade recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone 29F.1A12.1 / 10F.9G2.1)
In vivo grade recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / 29F.1A12.1)

Syd Labs provides the following recombinant anti-mouse PD-1 / PD-L1 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse PD-1 monoclonal antibodies (Clone: RMP1-14.1) for flow cytometry
Recombinant Anti-mouse PD-1 monoclonal antibodies (Clone: 29F.1A12.1) for flow cytometry
Recombinant Anti-mouse PD-L1 monoclonal antibodies (Clone: 10F.9G2.1) for flow cytometry

Recombinant PD1 and PDL1 Proteins:
Recombinant Human PD-1/PDCD1 Proteins
Biotinylated Recombinant Human PD-1/PDCD1 Proteins
Recombinant Mouse PD-1/PDCD1 Proteins
Biotinylated Recombinant Mouse PD-1/PDCD1 Proteins
Recombinant Cynomolgus PD-1/PDCD1 Proteins
Recombinant Canine PD-1/PDCD1 Proteins
Biotinylated Cynomolgus/Rhesus macaque PD-L1 Protein
Biotinylated Human PD-L1 Protein
Biotinylated Mouse PD-L1 Protein
Cynomolgus PD-L1 Protein
Cynomolgus/Rhesus macaque PD-L1 Protein
Human PD-L1/B7-H1 Protein
Mouse PD-L1/B7-H1 Protein

Related Links
Anti-Mouse PD 1 Monoclonal Antibodies(Clone RMP1-14.1)
Anti-Mouse PD1 Monoclonal Antibodies for Flow Cytometry(Clone: RMP1-14.1)
Anti-Mouse PD1 / PD1 Bispecific Antibodies(Clone RMP1-14.1 / 29F.1A12.1)
Anti-Mouse PD-1 / VEGF-A Bispecific Antibodies(Clone RMP1-14.1 / G6-31)
Anti-Mouse PD1 / PD-L1 Bispecific Antibodies(Clone RMP1-14.1 / 10F.9G2.1)
Super savings and terrific tips sent to your email inbox:

See our Privacy Policy

Best Sales of Products
D-Luciferin Potassium Salt
dNTP Mix, 10 mM each
dNTP mix, 25 mM each
Taq DNA Polymerases
2x High Yield PCR Master Mix
Reverse Transcriptases
2x Hot-start High-fidelity PCR Master Mix
Hot Start Taq DNA Polymerase
Hot-Start High-Fidelity DNA Polymerase
Anti-DNP Monoclonal Antibodies
Biotinylated Human PD-L1 Protein
Best Sales of Services
Rabbit Polyclonal Antibody Production Services
Mouse Monoclonal Antibody Production Services
Antibody Sequencing, Hybridoma Sequencing
Recombinant Antibody (IgG) Production Services
Recombinant Antibody (scFv) Production Services
Antibody Humanization Service
Generation of Stable Cell Lines Expressing Antibodies
Fc Fusion Protein Production Services
DNA Subcloning Services
Real-time PCR (qPCR) Service
Company
Contact Us
About Us
Our Distributors
Careers
Privacy Policy
Terms & Conditions
Sitemap
A  B  C  D  E  F  G  H  I
J  K  L  M  N  O  P  Q  R
S  T  U  V  W  X  Y  Z  0-9

Copyright © 2009-2026 sydlabs.com. All rights reserved.

Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.

Friend Link: Ushelf